Compare Agnico Eagle Mines Ltd (AEM) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs Amphastar Pharmaceuticals Inc — how do they compare? Agnico Eagle Mines Ltd trades at $181.5 (market cap $91.28B), while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: Agnico Eagle Mines Ltd is far larger — about 105.7× Amphastar Pharmaceuticals Inc's market cap, and Agnico Eagle Mines Ltd pays a 1% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AEM | AMPH | |
|---|---|---|
Market Cap | $91.28B | $863.95M |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $30.81 |
52-Week Low | $130.23 | $16.87 |
Enterprise Value | $88.12B | $1.26B |
Dividend Yield | 1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEM trades at $178.82, up 6.49% in the past 24 hours, reflecting strong momentum driven by record free cash flow and consistent earnings beats. The stock exhibits bullish technical signals with support at $177 and resistance at $181, while fundamentals show robust revenue growth to $11.91B in 2025 and a net income margin of 40.44%. Recent news highlights operational strength and gold price tailwinds.
Outlook remains positive with a consensus price target of $219.63, though risks include production costs and gold volatility. Analyst sentiment is strongly bullish with 21 buy ratings, supporting upside potential if execution continues.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
